Format

Send to

Choose Destination
See comment in PubMed Commons below
J Microbiol Immunol Infect. 2014 Feb;47(1):48-56. doi: 10.1016/j.jmii.2012.11.005. Epub 2013 Jan 26.

Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.

Author information

1
Department of Human Anatomy, College of Preclinical Medicine, Dali University, Dali 671000, China. Electronic address: deng13032871868@163.com.
2
Department of Human Anatomy, College of Preclinical Medicine, Dali University, Dali 671000, China.

Abstract

BACKGROUND:

We previously constructed a recombinant bacille Calmette-Guérin (rBCG-AE) strain that could express a fused Ag85A-ESAT-6 protein. That study suggested that the rBCG-AE strain was able to induce a higher titer of antibody and elicit a more long-lived and stronger Th1-type cellular immune responses than the parental BCG strain, the rBCG-A strain (i.e., expressing Ag85A), or the rBCG-E strain (i.e., expressing ESAT-6).

METHODS:

In the current study, we further investigated the strain's protective efficacy against Mycobacterium tuberculosis H37Rv infection in BALB/c mice through evaluating organ bacterial loads, lung histopathology, lung immunohistochemistry, and net weight gain or loss by using conventional BCG, rBCG-A, and rBCG-E as the controls.

RESULTS:

From the 3rd to 9th weeks after the challenge infection, the bacterial counts were significantly lower in tissues (e.g., spleen and lung tissues) in the mice immunized with rBCG-AE than in the control group, but were higher than the counts in the BCG group. The pathological damage in the lung tissues of the rBCG-AE group gradually improved from the 6th to 9th weeks after being infected with M. tuberculosis H37Rv, but the score of pathological changes in the rBCG-AE group was obviously higher than the score in the BCG group. There was no difference in the percentage of IFN-γ and iNOS positive cells in the lung tissues of the rBCG-AE and BCG groups.

CONCLUSION:

The results suggest that rBCG-AE can not promote protective efficacy against M. tuberculosis H37Rv infection, compared to the BCG vaccine.

KEYWORDS:

Ag85A; ESAT-6; Protective efficacy; Recombinant Mycobacterium bovis bacillus Calmette-Guérin (rBCG)

PMID:
23357605
DOI:
10.1016/j.jmii.2012.11.005
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center